These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

801 related items for PubMed ID: 31880796

  • 1. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
    Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, Filippov G, LoPresti A, Moline M.
    JAMA Netw Open; 2019 Dec 02; 2(12):e1918254. PubMed ID: 31880796
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder.
    Moline M, Zammit G, Cheng JY, Perdomo C, Kumar D, Mayleben D.
    J Clin Sleep Med; 2021 Jun 01; 17(6):1167-1174. PubMed ID: 33590823
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the treatment effectiveness between lemborexant and zolpidem tartrate extended-release for insomnia disorder subtypes defined based on polysomnographic findings.
    Inoue Y, Nishida M, Kubota N, Koebis M, Taninaga T, Muramoto K, Ishikawa K, Moline M.
    J Clin Sleep Med; 2023 Mar 01; 19(3):519-528. PubMed ID: 36472134
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of lemborexant in adults with insomnia: comparing Japanese and non-Japanese subgroups from the global, phase 3, randomized, double-blind, placebo-controlled SUNRISE 2 study.
    Inoue Y, Watanabe T, Takashima S, Takase T, Ishikawa K, Kubota N, Yardley J, Moline M.
    J Clin Sleep Med; 2021 May 01; 17(5):1067-1074. PubMed ID: 33576735
    [Abstract] [Full Text] [Related]

  • 5. Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study.
    Roth T, Krystal A, Steinberg FJ, Singh NN, Moline M.
    Sleep; 2013 Feb 01; 36(2):189-96. PubMed ID: 23372266
    [Abstract] [Full Text] [Related]

  • 6. Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.
    Citrome L, Juday T, Frech F, Atkins N.
    J Clin Psychiatry; 2021 Jun 01; 82():. PubMed ID: 34077032
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
    Roth T, Soubrane C, Titeux L, Walsh JK, Zoladult Study Group.
    Sleep Med; 2006 Aug 01; 7(5):397-406. PubMed ID: 16815744
    [Abstract] [Full Text] [Related]

  • 8. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.
    Murphy P, Moline M, Mayleben D, Rosenberg R, Zammit G, Pinner K, Dhadda S, Hong Q, Giorgi L, Satlin A.
    J Clin Sleep Med; 2017 Nov 15; 13(11):1289-1299. PubMed ID: 29065953
    [Abstract] [Full Text] [Related]

  • 9. Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder.
    Chepke C, Jain R, Rosenberg R, Moline M, Yardley J, Pinner K, Kumar D, Perdomo C, Filippov G, Atkins N, Malhotra M.
    Postgrad Med; 2022 Apr 15; 134(3):316-325. PubMed ID: 35254948
    [Abstract] [Full Text] [Related]

  • 10. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.
    Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T, ZOLONG Study Group.
    Sleep; 2008 Jan 15; 31(1):79-90. PubMed ID: 18220081
    [Abstract] [Full Text] [Related]

  • 11. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2.
    Kärppä M, Yardley J, Pinner K, Filippov G, Zammit G, Moline M, Perdomo C, Inoue Y, Ishikawa K, Kubota N.
    Sleep; 2020 Sep 14; 43(9):. PubMed ID: 32585700
    [Abstract] [Full Text] [Related]

  • 12. Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.
    McElroy H, O'Leary B, Adena M, Campbell R, Monfared AAT, Meier G.
    J Manag Care Spec Pharm; 2021 Sep 14; 27(9):1296-1308. PubMed ID: 34121443
    [Abstract] [Full Text] [Related]

  • 13. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M, Asnis GM, Shrivastava RK, Lydiard B, Bastani B, Sheehan DV, Roth T.
    J Clin Psychiatry; 2011 Jul 14; 72(7):914-28. PubMed ID: 21208597
    [Abstract] [Full Text] [Related]

  • 14. Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening.
    Murphy P, Kumar D, Zammit G, Rosenberg R, Moline M.
    J Clin Sleep Med; 2020 May 15; 16(5):765-773. PubMed ID: 32022664
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference.
    Black J, Pillar G, Hedner J, Polo O, Berkani O, Mangialaio S, Hmissi A, Zammit G, Hajak G.
    Sleep Med; 2017 Aug 15; 36():86-94. PubMed ID: 28735928
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients.
    Walsh JK, Soubrane C, Roth T.
    Am J Geriatr Psychiatry; 2008 Jan 15; 16(1):44-57. PubMed ID: 18165461
    [Abstract] [Full Text] [Related]

  • 17. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings.
    Roth T, Hull SG, Lankford DA, Rosenberg R, Scharf MB, Intermezzo Study Group.
    Sleep; 2008 Sep 15; 31(9):1277-84. PubMed ID: 18788653
    [Abstract] [Full Text] [Related]

  • 18. Exposure-Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia.
    Lalovic B, Savant Landry I, Moline M, Reyderman L, Hussein Z.
    J Clin Pharmacol; 2023 Apr 15; 63(4):498-511. PubMed ID: 36524428
    [Abstract] [Full Text] [Related]

  • 19. Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial.
    Yardley J, Kärppä M, Inoue Y, Pinner K, Perdomo C, Ishikawa K, Filippov G, Kubota N, Moline M.
    Sleep Med; 2021 Apr 15; 80():333-342. PubMed ID: 33636648
    [Abstract] [Full Text] [Related]

  • 20. Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials.
    Moline M, Zammit G, Yardley J, Pinner K, Kumar D, Perdomo C, Cheng JY.
    Postgrad Med; 2021 Jan 15; 133(1):71-81. PubMed ID: 33119423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.